Catalyst Pharmaceutical CPRX Equity Securities, FV-NI, Gain (Loss)

Equity Securities, FV-NI, Gain (Loss) at other companies

ALN

Alnylam PharmaceuticalsALNY

——

Other financials

Income statement

See full

Revenue$149.4M+5.6%

Gross profit$134.9M+9.2%

Operating income$73.2M+15.6%

Net income$63.7M+12.3%

EPS (diluted)$0.50+11.1%

Balance sheet

See full

Cash & equivalents$755.9M+30.2%

Total debt$2.7M-13.3%

Total equity$1.0B+27.5%

Total assets$1.1B+26.3%

Cash flow

See full

Operating cash flow$59.6M-0.8%

CapEx$27.0K—

Free cash flow$59.6M-0.8%

Valuation

See full

Market cap$3.84B+2.7%

Enterprise value$3.09B-4.1%

P/E17.4×-1.6×

P/S6.4×-0.6×

Profitability

See full

Gross margin86%-0.2pp

Operating margin44.8%+1.6pp

Net margin37.1%+0.2pp

FCF margin34.9%-15.2pp

Returns & leverage

See full

Return on equity24.5%-4.6pp

Debt / equity0×0.0×

Current ratio7.1×+1.0×

Where this comes from

Reported directly by Catalyst Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:EquitySecuritiesFvNiGainLoss.

The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Catalyst Pharmaceutical's equity securities, fv-ni, gain (loss).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Catalyst Pharmaceutical's equity securities, FV-NI, gain (loss)?: Catalyst Pharmaceutical (CPRX) reported equity securities, FV-NI, gain (loss) of $4.75M in Q1 2026.
How has Catalyst Pharmaceutical's equity securities, FV-NI, gain (loss) changed year-over-year?: Catalyst Pharmaceutical's equity securities, FV-NI, gain (loss) increased by 79.7% year-over-year, from $2.64M to $4.75M.